Shanghai clinical cohort for Parkinson's disease and multiple system atrophy (Reserve)

Shanghai Clinical Cohort - Parkinson's Disease (Reserve)

This project will try to use clinical exams, brain scans, electrical tests, genetic and biosample data from people with Parkinson's disease or multiple system atrophy to find early markers and better subtypes.

Quick facts

• Study type: Observational
• Enrollment: 700 (estimated)
• Sex: All
• Sponsor: Ruijin Hospital (Academic / other)
• Locations: 1 site (Shanghai)
• Trial ID: NCT07353463 on ClinicalTrials.gov

What this trial studies

This is a longitudinal observational cohort enrolling people with clinical Parkinson's disease and clinically probable multiple system atrophy in Shanghai. Participants will undergo standardized clinical assessments, multimodal imaging (MRI, PET/SPECT), electrophysiology, and biospecimen collection (blood, saliva, optional CSF) with long-term follow-up. Researchers will collect genetic data and compare 600 PD patients to 100 MSA patients to identify biomarkers, define precise subtypes, and model disease progression and treatment response. The assembled dataset is intended as a resource for translational research and development of novel therapies.

Who should consider this trial

Good fit: Adults with a clinical diagnosis of Parkinson's disease (per Chinese 2016 criteria) or clinically probable multiple system atrophy (per Chinese 2022 criteria) who are willing to provide informed consent, biospecimens, and undergo neuroimaging and clinical assessments are ideal candidates.

Not a fit: People who are unwilling or unable to provide biosamples, undergo imaging or follow-up visits, or who do not meet the clinical diagnostic criteria for PD or MSA are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, the cohort could enable earlier diagnosis, more precise subtyping, and better prediction of disease course to guide personalized care.

How similar studies have performed: Multimodal cohort efforts such as PPMI and other longitudinal PD cohorts have found promising biomarker signals and subtype patterns, but translation to routine clinical care remains limited and further validation is needed.

Eligibility criteria

* Inclusion Criteria for Clinical PD Group:

  1. Patients with a clinical diagnosis of Parkinson's disease (PD) according to the \_Chinese Diagnostic Criteria for Parkinson's Disease (2016 edition)\_.
  2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments.
  3. Provision of written informed consent
* Inclusion Criteria for Clinical MSA Group:

  1. Patients with a clinical diagnosis or clinically probable multiple system atrophy (MSA) according to the Chinese Expert Consensus on the Diagnostic Criteria for MSA (2022).
  2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments.
  3. Provision of written informed consent.
* Exclusion Criteria for All Participants:

  1. Patients with an unclear or uncertain diagnosis.
  2. History of stroke, head trauma, hydrocephalus, brain tumor, intracranial hypertension, or intracranial surgery.
  3. Evidence of intracranial organic lesions on CT/MRI.
  4. Severe anxiety, depression, or schizophrenia.
  5. Severe comorbidities involving the heart, lungs, liver, kidneys, endocrine system, or hematological system.
  6. Presence of aphasia, severe dysarthria, or other conditions that significantly impair clinical assessments.
  7. Anticipated poor compliance.

Where this trial is running

Shanghai

• Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, China (Recruiting)

Study contacts

• Study coordinator: Jun Liu, Professor

Conditions Parkinson's Disease; Multiple System Atrophy; observational cohort study; multimodal data; subtyping; long-term monitoring